New drug combo tested for Hard-to-Treat cancers

NCT ID NCT05514444

Completed Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tested a new drug called MK-4464, given alone or with another drug (pembrolizumab), in 64 people with advanced solid tumors that had not responded to standard treatments. The main goals were to check the safety of the drug and how the body processes it. This is a first step to see if the drug is safe enough for further testing.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED/METASTATIC SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic malignant neoplasm neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED/METASTATIC SOLID TUMORS NEOPLASMS

Contacts and locations

Locations

Amsterdam UMC, locatie VUmc ( Site 0400)

Amsterdam, North Holland, 1081HV, Netherlands
Hadassah Medical Center-Oncology ( Site 0302)

Jerusalem, 9112001, Israel
Nederlands Kanker Instituut - Antoni van Leeuwenhoek - NKI-AVL ( Site 0401)

Amsterdam, North Holland, 1066CX, Netherlands
Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 0201)

Toronto, Ontario, M5G 2M9, Canada
Rambam Health Care Campus-Oncology Division ( Site 0300)

Haifa, 3109601, Israel
The University of Louisville, James Graham Brown Cancer Center ( Site 0100)

Louisville, Kentucky, 40245, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.